MUC16 and ovarian cancer: In 2008, the US Preventive Services Task Force (USPSTF) issued a statement on “fair evidence” that ovarian cancer screening (consisting of ultrasound and CA125 tumor marker determination) had little effect on reducing mortality rates, while instead increasing the risk of harm (diagnostic operations, decline in quality of life).